Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04703322 2026-03-04

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Phase 2 Active not recruiting

9 enrolled 10 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02975700 2026-01-13

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

Phase NA Completed

6 enrolled 21 charts

Dermatologic

Melanoma

NCT04635111 2025-10-06

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Recruiting

30 enrolled

Giant Cell Tumor of Tendon Sheath

NCT04488822 2025-09-09

PLX3397

Phase 3 Active not recruiting

40 enrolled 15 charts

Giant Cell Tumor of Tendon Sheath

NCT02584647 2025-03-21

PLX3397

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma

Sarcoma, Neurofibrosarcoma

NCT02401815 2025-02-14

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Phase 1/2 Completed

51 enrolled 32 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT04526704 2024-12-30

PLX3397

Phase 4 Completed

32 enrolled 15 charts

Giant Cell Tumor of Tendon Sheath

NCT02371369 2022-05-11

ENLIVEN

Phase 3 Completed

120 enrolled 25 charts 1 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02734433 2022-04-25

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

Phase 1 Completed

12 enrolled 22 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01004861 2022-01-04

Safety Study of PLX108-01 in Patients With Solid Tumors

Phase 1 Completed

132 enrolled 28 charts

Other solid neoplasm

Solid Tumor

NCT02777710 2021-09-05

MEDIPLEX

Phase 1 Completed

48 enrolled

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02071940 2021-08-12

PIANO

Phase 2 Completed

7 enrolled

Dermatologic

Melanoma

NCT04223635 2021-06-22

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Phase EARLY_PHASE1 Completed

16 enrolled 22 charts

Giant Cell Tumor of Tendon Sheath

NCT03291288 2021-05-14

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Phase 1 Completed

32 enrolled 22 charts

Synovitis, Pigmented Villonodular

NCT03158103 2021-04-30

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Phase 1 Completed

3 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT02472275 2020-10-06

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Phase 1 Completed

8 enrolled

Genitourinary

Stage I Prostate Adenocarcinoma

NCT01596751 2020-07-17

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Phase 1/2 Completed

67 enrolled 19 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01217229 2020-06-30

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Completed

20 enrolled 7 charts

Lymphoid

Hodgkin Disease

NCT01790503 2020-06-30

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1/2 Completed

65 enrolled 26 charts

CNS

Glioblastoma

NCT01499043 2020-03-04

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Phase 2 Terminated

6 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT01349049 2020-03-02

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Completed

90 enrolled 23 charts

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Clinical Trials

I-SPY

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

PLX3397

PLX3397

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

PLX3397

ENLIVEN

Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors

Safety Study of PLX108-01 in Patients With Solid Tumors

MEDIPLEX

PIANO

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)